

Differences in the Stool Microbiome Before and After Colorectal Cancer Treatment

Running Title: Human Microbiome and Colorectal Cancer

Marc A Sze, Nielson T Baxter, Mack T Ruffin IV, Mary AM Rogers, and Patrick D Schloss[†]

Contributions: All authors were involved in the conception and design of the study. MAS analyzed the data. NTB processed samples and analyzed the data. All authors interpreted the data. MAS and PDS wrote the manuscript. All authors reviewed and revised the manuscript. All authors read and approved the final manuscript.

[†] To whom correspondence should be addressed: pschloss@umich.edu

Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI

Abstract

Colorectal cancer (CRC) continues to be a worldwide health problem with early detection being used as a key component in mitigating deaths due to the disease. Previous research suggests a link between stool bacterial microbiome and CRC. In this study, we used a model based on the microbiome, demographics, and prior medical history to classify individuals as having a lesion (i.e. adenoma or carcinoma). We then used this model to characterize the change in the gut microbiota before and after surgery. The overall objective was to investigate the changes in the microbiome after surgery in patients with adenomas or carcinomas. This model was tested on a 66 person group that included samples before and after treatment to allow for the assessment of how the model adjusts risk after treatment. The model used for prediction had an AUC of NA. For the follow up samples our Random Forest model significantly decreased the positive probability of lesion compared to the initial samples for both adenoma (P-value = $3.64e-11$) and carcinoma (P-value = $7.95e-08$). Our model predicted that 36.4% of the 67-person cohort had normal colons and 63.6% had a lesion. Some OTUs that changed the most before and after treatment included OTUs that were affiliated with members of *Blautia*, *Streptococcus* and *Escherichia/Shigella*. Our model suggests that treatment does significantly reduce the probability of having a colonic lesion. Further surveillance of these individuals will enable us to determine whether models such as the one we present here can also be used to predict recurrence of colorectal cancer.

21 **Importance**

22 This is one of the first studies to investigate within humans what happens to the bacterial
23 microbiome before and after adenoma and carcinoma treatment. Specifically, it aims to
24 assess how a random forest machine learning algorithm built model respond to treatment
25 and adjust it's positive probability calls of whether the individual has an adenoma or
26 carcinoma due to surgical removal of the lesion.

27 Introduction

28 Colorectal cancer (CRC) continues to be a leading cause of cancer related deaths and is
29 the second most common cancer death among men aged 40-79 years of age (1, 2). Over
30 the last few years death due to the disease has seen a significant decrease thanks mainly
31 to improvements in screening (1). However, despite this giant improvement there are still
32 approximately 50,000 deaths from the disease a year (2). It is estimated that around 5-10%
33 of all CRCs can be explained by autosomal dominant inheritance (3). The vast majority of
34 CRCs are not inherited and the exact etiology to disease has not been well worked out (2).
35 Although many risk factors have been identified (2) and non-invasive screening techniques
36 have started to be put into consistent use (4, 5) there has been a consistent increase in
37 the incidence of CRC in the younger population.

38 This increased incidence of CRC in the younger population is concerning since having
39 either an adenoma or carcinoma increases ones risk for future adenomas or carcinomas
40 (6–8). This increased risk can also carry with it an increased risk of mortality due to
41 this recurrence (9, 10). Therefore there has been a great amount of interest in early risk
42 stratification tools (11, 12) that can help identify those they may be at risk of recurrence.
43 Concurrently with this there has been a lot of interest in new areas such as the gut bacterial
44 microbiome for insight into potential disease pathology.

45 There has been promising work on the bacterial microbiome and it's ability to be able to
46 complement existing screening methods such as Fecal Immunoglobulin Test (FIT) or act
47 alone as a screening tool (13, 14). There has also been research into how this microbiome
48 could be altered directly on tumor tissue itself (15). There have also been a few studies
49 that have shown how this microbiome (16) or specific members within it (17) could be
50 directly involved with the pathogenesis of CRC. These studies have helped to provide a
51 tantalizing link between the bacterial microbiome and CRC. However, at this present time

there remains limited information on the bacterial microbiome before and after successful surgery for removal of the adenoma or carcinoma.

In this study we investigated what happened to the bacterial microbiome before and after surgery for both adenoma and carcinoma individuals. Our analysis includes both alpha and beta diversity analysis along with investigating individual operational taxonomic units (OTUs). We next utilized a Random Forest model that was trained on a completely separate data set and observed how this model as well as specific OTUs within this model performed on the initial and follow up samples. We then created a new model to classify initial and follow up samples and investigated how the model performs and what specific OTUs within the model change. Finally, we observed how specific bacteria that have been previously implicated in CRC changed before and after treatment in both the adenoma and carcinoma individuals.

Results

Bacterial Community and Fit Changes before and after Treatment Based on the *thetayc* distance metrics, comparing the initial to the follow up samples, there was no difference between the adenoma and carcinoma groups (P-value = 0.00198) [Figure 1a]. There was a difference in FIT between initial and follow up samples with the carcinoma group having a significant decrease in FIT versus the adenoma group (P-value = 2.15e-05) [Figure 1b]. Although the *thetayc* distance metric change was similar between adenoma and carcinoma the directionality of the change was significant in the cancer group between initial and follow up (P-value = 0.002) but not for the adenoma group (P-value = 0.997). This change can be visualized using an NMDS [Figure 1c & 1d]. When all follow up samples were compared to each other there was no significant overall difference between them (P-value = 0.085). There was no significant difference between initial and follow up samples for observed OTUs, Shannon diversity, or evenness after correction for multiple comparisons [Table S1]. Time of follow up sample from initial sampling, did not have a significant difference between adenoma and carcinoma (uncorrected P-value = 0.784).

Outcome of Model Training The range of the AUC for model training ranged from a minimum of 0.723 to a maximum of 0.795 with the middle of all 100 runs having an AUC of 0.761. Interestingly, the worst AUC model from training performed the best on it's respective 80/20 split test data [Figure 3]. In fact the 80/20 test performance showed that the AUC for the middle model chosen was the most stable (best training model test set AUC = 0.646, middle training model test set AUC = 0.744, worse training model test set AUC = 0.904). That is to say it had the smallest change in AUC in comparison to the minimum and maximum AUC trained models. The middle model was close to the full training data AUC NA. There was no significant difference between the AUC of the best and middle training models (P-value = 1). There was also no difference in the middle model versus worse (P-value = 0.0431) or full data model (P-value = 1). The two comparisons

with a significant difference were between the worse training model and the best training model (P-value = 6.83×10^{-4}) and the worse training model and full training model (P-value = 1.2×10^{-3}).

Most Important Variables to the Model Overall, there were a total of 37 variables identified as being present in more than 50% of the training models [Figure S2]. The top 5 most important bacterial OTUs were Lachnospiraceae (Otu000013), Escherichia/Shigella (Otu000018), Ruminococcaceae (Otu000020), Ruminococcus (Otu000017), and Porphyromonas (Otu000153). These 5 OTUs were present in at least 90 out of the total 100 different 80/20 runs.

Surgical Removal of an Adenoma or Carcinoma Results in a Decrease in Positive Probability Prediction A total of 1 sample was omitted from the original 67 test sample set since it was missing a complete set of follow up data. This left a total of 66 samples for test predictions. After multiple comparison correction there was a significant overall decrease in positive probability of a carcinoma and adenoma (P-value = 1.11×10^{-11}) [Figure 4]. This decrease was significant for both adenoma (P-value = 3.64×10^{-11} [Figure 4a] and carcinoma (P-value = 7.95×10^{-8}) [Figure 4b] alone. This decrease in probability of lesion also held specifically for those with screen relative neoplasias (SRN) (P-value = 7.63×10^{-6}). A total of 66 or 100% of all samples were correctly predicted to have a lesion. Although there was a decrease in positive probability only 24 of the total 66 individuals were classified as adenoma or carcinoma free on follow up (successful classification of 37.9%). There was no significant difference between the predictions and actual diagnosis for the initial samples in the 67-sample cohort test set. However, the predictions were significantly discordant with the diagnosis for the follow up samples (P-value = 4.19×10^{-10}). Although there were discordant results the respective sensitivity for the initial group was 100% and for follow up was 100%, respectively.

There was 1 individual who still clearly had CRC on follow up as well as 5 individuals

whose status on follow up was unknown. Although the 1 individual had a decrease in positive probability their follow up sample was still higher than the cutoff threshold of 0.5 (positive probability = 0.903). Interestingly, 1 individuals who were unknown on follow up still were over the threshold cutoff of 0.5 even though, like the 1 individual with clear CRC on follow up, the probability of an adenoma or carcinoma decreased [Table S2].

The follow up positive probabilities were not affected by either chemotherapy treatment (uncorrected P-value = 0.621) or radiation therapy (uncorrected P-value = 0.255). There was also no difference in the amount of change in the positive probability based on whether individuals received chemotherapy (uncorrected P-value = 0.718) or radiation therapy (uncorrected P-value = 0.431).

Specific OTUs in the Lesion Model are not Detected in Follow Up Versus Initial Samples Overall, there were a total of 11 OTUs that were common between the main lesion model and the model for classifying initial and follow up samples specifically [Table S3]. A total of 1 OTU was still significant after multiple comparison correction and it's lowest taxonomic identification was to Blautia. In general, Otu000012 (Blautia) was decreased from initial to follow up [Figure 5]. The relative abundance was not drastically different then the mean of the values observed in the control training set [Figure 5].

Differences in Adenoma and Carcinoma in Previously Associated Cancer Bacteria First, there was a clear magnitude difference in these specific OTUs based on whether they were from adenoma or carcinoma individuals [Figure 6]. The carcinoma samples showed a significant difference between initial and follow up samples for *Peptostreptococcus stomatis* (P-value = 0.0183) and *Porphyromonas asaccharolytica* (P-value = 0.0154) whereas there were no significant differences in any of these OTUs in the adenoma samples [Table S4].

Discussion

In our training set we show that the overall community structure as measured by different alpha diversity metrics, shows very little change between controls and those with either adenoma or carcinoma [Table S1]. With respect to our test set there was very little difference in magnitude of change in the thetayc distance metric between those with adenoma or carcinoma [Figure 1a]. In contrast, FIT had a large change in the initial and follow up samples in the carcinoma group versus the adenoma [Figure 1b]. An NMDS showed that there was very little observable change between initial and follow up for the adenoma group but there was one for the carcinoma group [Figure 1c & 1d]. This cursory information is suggestive that treatment of carcinoma, had the largest response.

We next created a model that incorporated both patient metadata, FIT, and the bacterial microbiome to be able to predict lesions (adenoma or carcinoma). Our middle training model, based on AUC, from 100 80/20 (train/test) splits was similar to the full training data model. It's 10-fold cross validated AUC was similar to it's test set AUC which was not the case for both the best and worse training model [Figure 3]. Using the full training data model we predicted the probability of a lesion in the initial and follow up samples [Figure 4]. There was a significant decrease in positive probability regardless of whether the sample was a carcinoma or adenoma. The overall sensitivity for lesion detection in the initial samples was 100 and for follow ups was 100. Although there was a decrease in overall probability of an adenoma or carcinoma only 24 were below the 0.5 threshold out of the total 65 individuals who were diagnosed as not having a carcinoma on follow up.

We then investigated which OTUs could potentially be more important in our model [Figure 5 & Table S3]. Many of the OTUs identified classified to normal flora bacterium [Table S3]. Only a single OTU though was significant after multiple comparison correction and the lowest taxonomic identification of Otu000012 was to *Blautia*. Although there was a

164 difference in the relative abundance at initial and follow up these values were not drastically
165 different from the relative abundance values observed in the control individuals of the
166 training set [Figure 5]. Although we were interested in what we could use to classify those
167 with either adenoma or carcinoma versus normal. We found that the traditional bacteria
168 associated with CRC were higher in magnitude in the carcinoma group and there were
169 significant differences in some of these OTUs between the initial and follow up samples
170 [Figure 5 and Tabl S5]. This research provides evidence that it is possible to use bacterial
171 microbiome data to create a highly sensitive model, that is reactive to therapy, for detection
172 of adenoma or carcinoma. It accomplishes this by using a unique sample set in which
173 before and after surgery stool samples are available for assessment. By using these
174 types of samples we are not only able to show sensitivity of lesion prediction but also able
175 to show that this model is reactive. That is to say that after surgery for removal of the
176 adenoma or carcinoma it decreases the positive probability to reflect a lower likelihood of
177 the individual having an adenoma or carcinoma.

178 This study builds upon previous work from numerous labs that have looked into the bacterial
179 microbiome as a potential screening tool (**insert citation**). Based on previous work by
180 Jobin, et al. (**insert citation**) it may not be surprising to see E.coli in the top 5 OTUs for
181 this model. Similarly, Porphyromonas has also been implicated in colorectal cancer (**insert**
182 **citation**). Interestingly, many of the other OTUs had taxonomic identification for resident
183 gut microbes. This could suggest that changes to the resident microbiome are important
184 to the initiation of adenoma or carcinoma formation (**insert citation**) and provide support
185 for the hypothesis that an initial change in the bacterial microbiome could pave the way for
186 more inflammatory species: whether by creation of a new niche for oral microbes (**insert**
187 **citation**) or allowing for a bloom of existing pro-inflammatory residents (**insert citation**).

188 Naturally, it is curious that normal staples of many screening studies such as
189 Fusobacterium, Parvimonas, and Peptostreptococcus were not present in the majority

of the training models. One potential explanation for this is that FIT provides the same information to the model as these three organisms and so the model uses FIT preferentially over them. This has been suggested to be the case in a previous study (**insert Baxter Study**). It is also possible that these specific bacteria play a major role in the progression to carcinoma but may not be as important in the initiation of an adenoma, which would be supported by our data [Figure 5]. Regardless, our study does not argue against the importance of these bacterium in CRC initiation or pathogenesis but rather that the model does not utilize these specific bacteria for prediction purposes. Another potential reason why we did not identify the “usual suspects” is that these bacteria may not change much between initial and follow up samples in those with an identified lesion. That is to say that the bacteria are consistently present even after removal of the lesion by surgery. Finally, it is likely that within our test set there was not enough individuals in which detection was made or relative abundance high enough for these bacteria to be significant using a paired wilcoxon test.

One limitation in this study is that we do not know whether individuals in our test set eventually had a subsequent CRC diagnosis. This information would help to strengthen the case for our Random Forest based model keeping a number of individuals above the cutoff threshold even though at follow up they were diagnosed as no longer having a lesion. Another limitation is that we do not know if adding modern tests such as the stool DNA test (**insert citation**) could help improve our overall AUC. Another limitation is that this study drew heavily from those with caucasian ancestry. The results may not be immediately representative of those with either Asian or African ancestry. Finally, although our training and test set are relatively large we still run the risk of overfitting or having a model that may not be immediately extrapolateable to other populations. We’ve done our best to safeguard against this by not only running 10-fold cross validation but also having over 100 different 80/20 splits to try and mimic the type of variation that might be expected to occur.

216 By adding patient data such as age, BMI, etc. to the model and showing that it can
217 successfully help to predict both carcinoma and adenoma our study provides further data
218 that these patient factors in conjunction with the bacterial microbiome could potentially
219 influence CRC and perhaps have a role in formation of adenomas. Further studies need to
220 be carried out to verify our findings since not only are we dealing with stool, which could
221 be very different than the communities present on the actual tissue, but also are dealing
222 with correlations that may not be representative of the true pathogenesis of disease.

223 Despite these limitations we think that these findings significantly add to the existing
224 scientific knowledge on CRC and the bacterial microbiome. The ability for machine
225 learning algorithms to take bacterial microbiome data and successfully lower positive
226 probability after either adenoma or carcinoma removal provides evidence that there are
227 specific signatures associated with these lesions. It also shows that these algorithms can
228 not only successfully react to successful treatment regimens but also may be able to one
229 day diagnose CRC with a high level of accuracy.

Methods

Study Design and Patient Sampling The sampling and design of the study was similar to that reported in Baxter, et al (13). In brief, study exclusion involved those who had already undergone surgery, radiation, or chemotherapy, had colorectal cancer before a baseline stool sample could be obtained, had IBD, a known hereditary non-polyposis colorectal cancer, or Familial adenomatous polyposis. Samples used to build the model used for prediction were collected either prior to a colonoscopy or between 1 - 2 weeks after. The bacterial microbiome has been shown to normalize within this time period (18). Kept apart from this training set were a total of 67 individuals that not only had a sample as described previously but also a follow up sample between 188 - 546 days after surgery and treatment had been completed. This study was approved by the University of Michigan Institutional Review Board. All study participants provided informed consent and the study itself conformed to the guidelines set out by the Helsinki Declaration.

Fecal Immunochemical Test and 16S rRNA Gene Sequencing FIT was analyzed as previously published using both OC FIT-CHEK and OC-Auto Micro 80 automated system (Polymedco Inc.) (19). 16S rRNA gene sequencing was completed as previously described by Kozich, et al. (20). In brief, DNA extraction used the 96 well Soil DNA isolation kit (MO BIO Laboratories) and an epMotion 5075 automated pipetting system (Eppendorf). The V4 variable region was amplified and the resulting product was split between three sequencing runs with control, adenoma, and carcinoma evenly represented on each run. Each group was randomly assigned to avoid biases based on sample collection location.

Sequence Processing The mothur software package (v1.37.5) was used to process the 16S rRNA gene sequences. This process has been previously described (20). The general processing workflow using mothur is as follows: Paired-end reads were first merged into contigs, quality filtered, aligned to the SILVA database, screening for chimeras,

classified with a naive Bayesian classifier using the Ribosomal Database Project (RDP), and clustered into Operational Taxonomic Units (OTUs) using a 97% similarity cutoff with an average neighbor clustering algorithm. The number of sequences for each sample was rarified to 10521 in an attempt to minimize uneven sampling.

Lesion Model Creation The Random Forest (21) algorithm was used to create the model used for prediction of lesion (adenoma or carcinoma) for the 67 individuals with follow up samples. The model included data on FIT and the bacterial microbiome. Non-binary data was checked for near zero variance and auto correlation. Data columns that had near zero variance were removed. Columns that were correlated with each other over a Spearman correlation coefficient of 0.75 had one of the two columns removed. This pre-processing was performed with the R package caret (v6.0.73). Optimization of the mtry hyperparameter involved taking the samples and making 100 80/20 (train/test) splits in the data where control and lesion were equally represented in the 80 and 20 split, respectively. This 80% portion was then split again into an 80/20 split, and run through 20 repeated 10-fold cross validations to optimize the model's AUC (Area Under the Curve of the Receiver Operator Characteristic). This resulting model was then tested on the 20% of the data that was originally held out from this overall process. Once the ideal mtry was found the entire 490 sample set was used to create the final Random Forest model on which testing on the 67-person cohort was completed. The default cutoff of 0.5 was used as the threshold to classify individuals as positive or negative for lesion. The hyperparameter, mtry, defines the number of variables to investigate at each split before a new division of the data is created.

Initial Follow Up Model Creation We also investigated whether a model could be created that could identify before and after surgery samples. The training set utilized the 67-person cohort that was previously used for testing of the lesion model. The creation of this model and optimization of the mtry hyperparameter was completed using the same procedure

that was used to create the lesion model.

Selection of Important OTUs In order to assess which variables were most central to all the models we counted the number of times a variable was present in the top 10% of mean decrease in accuracy (MDA) for each different 80/20 split model and then filtered this list to variables that were only present more than 50% of the time. This final collated list of variables was what was considered the most important for the lesion or initial follow up models.

Statistical Analysis The R software package (v3.3.2) was used for all statistical analysis. Comparisons between bacterial community structure utilized PERMANOVA (22) in the vegan package (v2.4.1) while comparisons between ROC curves utilized the method by DeLong et al. (23) executed by the pROC (v1.8) package. Comparisons between probabilities as well as overall amount of OTU between initial and follow up samples utilized a paired wilcoxon ranked sum test. Where multiple comparison testing was needed a Benjamini-Hochberg (BH) correction was applied (24) and a corrected P-value of less than 0.05 was considered significant. Unless otherwise stated the P-values reported are those of the BH corrected ones.

Analysis Overview Differences in FIT between initial and follow ups for either adenoma or carcinoma were investigated. Next, initial and follow up samples were analyzed for differences in alpha and beta diversity. All OTUs used in the lesion model were also analyzed using a paired wilcoxon test. The lesion model was then tested for accuracy in prediction and whether it reduced the positive probability of lesion after surgery. The most important OTUs for this were used to build an updated model and this reduced feature model was assessed for it's similarity to the original model. We then used the initial follow up model to assess whether this model could classify samples better than the lesion model. The most important OTUs were then identified from this model and used to create a reduced feature initial follow up model. This reduced feature model, as was

done with the lesion model, was compared to the full model for loss of accuracy. Finally, in order to investigate the relative abundance of specific bacteria, that have been previously associated with CRC, we selected OTUs that taxonomically classified to *Fusobacterium Nucleatum*, *Parvimonas Micra*, *Peptostreptococcus Assacharolytica*, and *Porphyromonas Stomatis*. Specifically, we wanted to test if there were any differences based on whether the individual had an adenoma or carcinoma.

Reproducible methods. A detailed and reproducible description of how the data were processed and analyzed can be found at https://github.com/SchlossLab/Size_followUps_2017.

Acknowledgements

The authors thank the Great Lakes-New England Early Detection Research Network for providing the fecal samples that were used in this study. This study was supported by funding from the National Institutes of Health to P. Schloss (R01GM099514, P30DK034933) and to the Early Detection Research Network (U01CA86400).

Figure 1: Changes and differences between the adenoma or carcinoma group. A)

No significant difference was found between the adenoma and carcinoma group for the t-test (P-value = 0.00198). B) A significant difference was found between the adenoma and carcinoma group for FIT (P-value = 2.15×10^{-5}). C) NMDS of the initial and follow up samples for the Adenoma group. D) NMDS of the initial and follow up samples for the Carcinoma group. For C) and D) the teal represents initial samples and the pink represents follow up samples.

Figure 2: Previously Associated CRC Bacteria in Initial and Follow up Samples. A)

Carcinoma initial and follow up samples. There was a significant difference in initial and follow up sample for the OTUs classified as *Peptostreptococcus stomatis* (P-value = 0.0183) and *Porphyromonas asaccharolytica* (P-value = 0.0154). B) Adenoma initial and follow up samples. There were no significant differences between initial and follow up.

Figure 3: Graph of the Receiver Operating Characteristic Curve for lesion and

Initial/Follow up models. The shaded areas represent the range of values of a 100 different 80/20 splits of the test set data using either all variables (grey) or reduced variable (red) models. The blue line represents the reduced variable model using 100% of the data set. A) Lesion model. B) Initial/Follow up model

Figure 4: Breakdown by Carcinoma and Adenoma of Prediction Results for Initial

and Follow Up* A) Positive probability adjustment of those with carcinoma from initial to follow up sample B) Positive probability adjustment of those with adenoma as well as those with SRN and the probability adjustment from initial to follow up sample. The dotted line represents the threshold used to make the decision of whether a sample was lesion positive or not.

Figure 5: Lesion Model OTU with a Significant Decrease in Relative Abundance

that is also Predictive of Initial and Follow Up. After multiple comparison correction 1

346 (Blautia) was the only one with a P-value < 0.05. The dotted line represents the average
347 relative abundance in the control training group.

Figure S1: Distribution of P-values from Paired Wilcoxon Analysis of OTUs in Initial versus Follow Up

Figure S2: Summary of Important Variables in both Lesion and Initial/Follow Up models A) MDA of the most important variables in the lesion model. The black point represents the median and the different colors are the different runs up to 100. B) The total number of appearances of each variable in the 100 different lesion models. The cutoff of 50% was used to assess importance.

Figure S3: Thetayc Graphed Against Time of Follow up Sample from Initial

References

1. **Jemal A, Siegel R, Xu J, Ward E.** 2010. Cancer statistics, 2010. *CA: a cancer journal for clinicians* **60**:277–300. doi:10.3322/caac.20073.
2. **Hagggar FA, Boushey RP.** 2009. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. *Clinics in Colon and Rectal Surgery* **22**:191–197. doi:10.1055/s-0029-1242458.
3. **Green RC, Green JS, Buehler SK, Robb JD, Daftary D, Gallinger S, McLaughlin JR, Parfrey PS, Younghusband HB.** 2007. Very high incidence of familial colorectal cancer in Newfoundland: A comparison with Ontario and 13 other population-based studies. *Familial Cancer* **6**:53–62. doi:10.1007/s10689-006-9104-x.
4. **Liao C-S, Lin Y-M, Chang H-C, Chen Y-H, Chong L-W, Chen C-H, Lin Y-S, Yang K-C, Shih C-H.** 2013. Application of quantitative estimates of fecal hemoglobin concentration for risk prediction of colorectal neoplasia. *World Journal of Gastroenterology* **19**:8366–8372. doi:10.3748/wjg.v19.i45.8366.
5. **Johnson DH, Kisiel JB, Burger KN, Mahoney DW, Devens ME, Ahlquist DA, Sweetser S.** 2016. Multi-target stool DNA test: Clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. *Gastrointestinal Endoscopy*. doi:10.1016/j.gie.2016.11.012.
6. **Laiyemo AO, Doubeni C, Brim H, Ashktorab H, Schoen RE, Gupta S, Charabaty A, Lanza E, Smoot DT, Platz E, Cross AJ.** 2013. Short- and long-term risk of colorectal adenoma recurrence among whites and blacks. *Gastrointestinal Endoscopy* **77**:447–454. doi:10.1016/j.gie.2012.11.027.
7. **Matsuda T, Fujii T, Sano Y, Kudo S-e, Oda Y, Igarashi M, Iishi H, Murakami Y,**

Ishikawa H, Shimoda T, Kaneko K, Yoshida S. 2009. Five-year incidence of advanced neoplasia after initial colonoscopy in Japan: A multicenter retrospective cohort study. *Japanese Journal of Clinical Oncology* **39**:435–442. doi:10.1093/jjco/hyp047.

8. Ren J, Kirkness CS, Kim M, Asche CV, Puli S. 2016. Long-term risk of colorectal cancer by gender after positive colonoscopy: Population-based cohort study. *Current Medical Research and Opinion* **32**:1367–1374. doi:10.1080/03007995.2016.1174840.

9. Løberg M, Kalager M, Holme Ø, Hoff G, Adami H-O, Bretthauer M. 2014. Long-term colorectal-cancer mortality after adenoma removal. *The New England Journal of Medicine* **371**:799–807. doi:10.1056/NEJMoa1315870.

10. Freeman HJ. 2013. Natural history and long-term outcomes of patients treated for early stage colorectal cancer. *Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie* **27**:409–413.

11. Lee JH, Lee JL, Park IJ, Lim S-B, Yu CS, Kim JC. 2016. Identification of Recurrence-Predictive Indicators in Stage I Colorectal Cancer. *World Journal of Surgery*. doi:10.1007/s00268-016-3833-2.

12. Richards CH, Ventham NT, Mansouri D, Wilson M, Ramsay G, Mackay CD, Parnaby CN, Smith D, On J, Speake D, McFarlane G, Neo YN, Aitken E, Forrest C, Knight K, McKay A, Nair H, Mulholland C, Robertson JH, Carey FA, Steele R, Scottish Surgical Research Group. 2016. An evidence-based treatment algorithm for colorectal polyp cancers: Results from the Scottish Screen-detected Polyp Cancer Study (SSPoCS). *Gut*. doi:10.1136/gutjnl-2016-312201.

13. Baxter NT, Ruffin MT, Rogers MAM, Schloss PD. 2016. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome*

Medicine **8**:37. doi:10.1186/s13073-016-0290-3.

14. **Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Tran Van Nhieu J, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, Knebel Doeberitz M von, Sobhani I, Bork P.** 2014. Potential of fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology* **10**:766.

15. **Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, Peterson SN, Snedrud EC, Borisy GG, Lazarev M, Stein E, Vadivelu J, Roslani AC, Malik AA, Wanyiri JW, Goh KL, Thevambiga I, Fu K, Wan F, Llosa N, Housseau F, Romans K, Wu X, McAllister FM, Wu S, Vogelstein B, Kinzler KW, Pardoll DM, Sears CL.** 2014. Microbiota organization is a distinct feature of proximal colorectal cancers. *Proceedings of the National Academy of Sciences of the United States of America* **111**:18321–18326. doi:10.1073/pnas.1406199111.

16. **Zackular JP, Baxter NT, Chen GY, Schloss PD.** 2016. Manipulation of the Gut Microbiota Reveals Role in Colon Tumorigenesis. *mSphere* **1**. doi:10.1128/mSphere.00001-15.

17. **Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, Fodor AA, Jobin C.** 2014. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. *Nature Communications* **5**:4724. doi:10.1038/ncomms5724.

18. **O'Brien CL, Allison GE, Grimpén F, Pavli P.** 2013. Impact of colonoscopy bowel preparation on intestinal microbiota. *PloS One* **8**:e62815. doi:10.1371/journal.pone.0062815.

19. **Daly JM, Bay CP, Levy BT.** 2013. Evaluation of fecal immunochemical tests for colorectal cancer screening. *Journal of Primary Care & Community Health* **4**:245–250.

doi:10.1177/2150131913487561.

20. **Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD.** 2013. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Applied and Environmental Microbiology* **79**:5112–5120. doi:10.1128/AEM.01043-13.

21. **Breiman L.** 2001. Random Forests. *Machine Learning* **45**:5–32. doi:10.1023/a:1010933404324.

22. **Anderson MJ, Walsh DCI.** 2013. PERMANOVA, ANOSIM, and the Mantel test in the face of heterogeneous dispersions: What null hypothesis are you testing? *Ecological Monographs* **83**:557–574. doi:10.1890/12-2010.1.

23. **DeLong ER, DeLong DM, Clarke-Pearson DL.** 1988. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. *Biometrics* **44**:837–845.

24. **Benjamini Y, Hochberg Y.** 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological)* **57**:289–300.